Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)

Next Previous
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azemiglitazone (Primary)
  • Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Acronyms EMMINENCE
  • Sponsors Cirius Therapeutics

    • Most Recent Events

    • 24 Jun 2023 Results assessing the serological extracellular matrixbiomarkers PRO-C3, PRO-C4 and PRO-C6, which serve as surrogates of fibroblast activity, pericellular fibrosis formation and the profi-brotic and proinflammatory fragment endotrophin , presented at the European Association for the Study of the Liver Congress 2023
    • 29 Jun 2021 Results assessing Branched-Chain Amino Acid Catabolism(BCAA) from plasma collected from this trial, presented at the 81st Annual Scientific Sessions of the American Diabetes Association.
    • 26 Jun 2021 Results assessing the novel graph neural network (GNN) approach that combines interpretability with performance for NASH scoring, presented at The International Liver Congress 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top